Mads Hald Andersen
Overview
Explore the profile of Mads Hald Andersen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
180
Citations
3313
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bentivegna S, Almosailleakh M, Zhao L, Schuster M, Benquet S, Balhuizen A, et al.
Exp Hematol Oncol
. 2025 Jan;
14(1):10.
PMID: 39885602
Clonal hematopoiesis of indeterminate potential (CHIP) is a condition where blood or bone marrow cells carry mutations associated with hematological malignancies. Individuals with CHIP have an increased risk of developing...
2.
Martinenaite E, Lecoq I, Aaboe-Jorgensen M, Ahmad S, Perez-Penco M, Glockner H, et al.
J Immunother Cancer
. 2025 Jan;
13(1).
PMID: 39880485
Background: Arginase-1 (Arg1) expressing tumor-associated macrophages (TAMs) may create an immune-suppressive tumor microenvironment (TME), which is a significant challenge for cancer immunotherapy. We previously reported the existence of Arg1-specific memory...
3.
Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E, et al.
J Hematol Oncol
. 2025 Jan;
18(1):6.
PMID: 39806516
The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, and signaling molecules that interact to promote...
4.
Perez-Penco M, Byrdal M, Lara de la Torre L, Ballester M, Khan S, Siersbaek M, et al.
Cell Mol Immunol
. 2024 Dec;
22(1):111-126.
PMID: 39653766
Although interleukin (IL)-6 is considered immunosuppressive and tumor-promoting, emerging evidence suggests that it may support antitumor immunity. While combining immune checkpoint inhibitors (ICIs) and radiotherapy in patients with pancreatic cancer...
5.
Holmstrom M, Ruders J, Riley C, Larsen M, Grauslund J, Kjaer L, et al.
Br J Haematol
. 2024 Aug;
205(4):1417-1429.
PMID: 39161981
Recently, an antibody which inhibits the glycoprotein A repetitions predominant (GARP)-mediated release of active transforming growth factor beta (TGFβ) from the TGFβ propeptide latency-associated peptide (LAP) showed preclinical activity in...
6.
Hulen T, Friese C, Kristensen N, Granhoj J, Holz Borch T, Peeters M, et al.
Front Immunol
. 2024 Aug;
15:1462081.
PMID: 39091496
[This corrects the article DOI: 10.3389/fimmu.2023.1180997.].
7.
Bentivegna S, Come C, Porse B, Andersen M, Gronbaek K
Br J Haematol
. 2024 Jul;
205(3):1220-1224.
PMID: 39031600
No abstract available.
8.
Strum S, Andersen M, Marie Svane I, Siu L, Weber J
Am Soc Clin Oncol Educ Book
. 2024 Apr;
44(3):e438592.
PMID: 38669611
The origins of cancer vaccines date back to the 1800s. Since then, there have been significant efforts to generate vaccines against solid and hematologic malignancies using a variety of platforms....
9.
Perez-Penco M, Lara de la Torre L, Lecoq I, Martinenaite E, Andersen M
J Immunother Cancer
. 2024 Feb;
12(2).
PMID: 38417917
The tumor microenvironment (TME) of pancreatic cancer is highly immunosuppressive. We recently developed a transforming growth factor (TGF)β-based immune modulatory vaccine that controlled tumor growth in a murine model of...
10.
Glockner H, Martinenaite E, Landkildehus Lisle T, Grauslund J, Ahmad S, Met O, et al.
Oncoimmunology
. 2024 Feb;
13(1):2318053.
PMID: 38404966
Arginase-1 (Arg1) is expressed by regulatory myeloid cells in the tumor microenvironment (TME), where they play a pro-tumorigenic and T-cell suppressive role. Arg1-specific CD4+ and CD8+ memory T cells have...